Sorin Group’s next-gen DES
This article was originally published in The Gray Sheet
Executive Summary
Firm has launched its Janus Flex tacrolimus-eluting Carbostent system in Europe, Sorin announces Feb. 21. With many of the same safety and efficacy components of the company's first-generation product - including a polymer-free design that relies on reservoirs on the stent's outer surface for targeted drug release - the firm claims Janus Flex features an improved catheter tip to facilitate deliverability and conformability in difficult-to-access anatomy...
You may also be interested in...
Sorin stent
Chrono cobalt chrome stent launches in Europe following CE mark receipt April 4. Sorin claims that in comparison to stainless steels stents, Chrono offers better mechanical strength, flexibility and radiopacity. The device features two radiopaque markers at each end to aid in placement at the target lesion as well as a bio-compatible coating to reduce stent thrombosis. In February, the firm launched the Janus Flex tacrolimus-eluting stent in Europe (1"The Gray Sheet" Feb. 27, 2006, In Brief)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.